Patient-Reported Visual Function from the Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion, Including Macular Hole (Oasis) Study
Retina (Philadelphia, Pa.)
PURPOSE: To evaluate patient-reported visual function after ocriplasmin through the 25-item National Eye Institute Visual Function Questionnaire (VFQ-25) in patients with symptomatic vitreomacular adhesion/vitreomacular traction including macular hole.
METHODS: This was a prespecified analysis of a secondary endpoint from the OASIS trial. Patients received a single intravitreal injection of ocriplasmin (0.125 mg) or sham and completed the VFQ-25 questionnaire at baseline and at Months 6, 12, and 24. Clinically meaningful (≥5-point) changes from baseline were assessed.
RESULTS: Of the 220 patients enrolled, 146 received ocriplasmin and 74 received sham. At Month 24, the percentage of patients with a ≥5-point improvement from baseline in VFQ-25 composite scores was higher with ocriplasmin versus sham (51.4% vs. 30.1%, 95% confidence interval, 8.1-34.5, P = 0.003). The percentage of patients with ≥5-point worsening at Month 24 was lower with ocriplasmin versus sham (9.5% vs. 15.6%, 95% confidence interval: -15.6 to 3.5, P = 0.191). A larger percentage of patients treated with ocriplasmin versus sham experienced a ≥5-point improvement in VFQ-25 composite and subscale scores at Month 24 regardless of baseline full-thickness macular hole status.
CONCLUSION: A larger percentage of patients with symptomatic vitreomacular adhesion/vitreomacular traction reported clinically meaningful improvements in self-assessed visual function with ocriplasmin than sham.
Mein C, Dugel PU, Feiner L, Drenser K, Miller D, Benz M, Meunier E, Moro L, Fineman MS. Patient-Reported Visual Function from the Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion, Including Macular Hole (Oasis) Study. Retina. 2020 Jul;40(7):1331-1338. doi: 10.1097/IAE.0000000000002599. PMID: 31259807; PMCID: PMC7302331.